Pharma doesn’t “guess” when exclusivity ends. It tracks it—down to the day—because the next patent term can be the difference between blockbuster continuity and a cliff.
That’s the real story behind how companies monitor IND and NDA timelines to positi…

Pharma doesn’t “guess” when exclusivity ends. It tracks it—down to the day—because the difference between a clean win and a costly loss is often measured in months, not years.
In a world where patent cliffs, regulatory timelines, and jurisdiction-by-ju…

Generics are no longer “copy and paste.” They’re a precision science—and the winners are the ones who treat bioequivalence like a product, not a checkbox.
If you’ve spent any time around ANDA strategy, you already know the headline: complex generics ar…

Pharma is running a talent race—just not the one most people think.
In hiring, companies often wait until a role opens, a competitor makes a move, or a recruiter flags a candidate. But in drug development, timing is everything. The same principle that …

Pharma patent litigation is often sold as a legal problem.
But the real cost isn’t the attorney invoice you see in the headlines. It’s the economic drag that starts the moment a case is filed—and keeps compounding long after the final brief is submitte…

Australia’s “drug patent clock” sounds simple—until you watch it run.
In theory, patents are time-limited exclusivity. In practice, the clock can stretch, pause, restart, and—depending on how you measure it—end up meaning something very different for p…

Pharma doesn’t always need a “new drug” to extend its profits. Often, it just needs a new story.
That’s the core idea behind the reformulation playbook described in a recent DrugPatentWatch piece: how companies use the 505(b)(2) pathway to secure addit…

Pharma procurement teams don’t lose money because they lack spreadsheets.
They lose money because they’re buying in the dark.
Most organizations still negotiate drug spend as if patent cliffs are random weather—something you react to after the fact. Bu…

The “Drug Patent Cliff” Isn’t a Legal Problem—It’s a Procurement Problem. Here’s the Playbook.
If you manage sourcing, contracting, or formulary strategy, you already know the uncomfortable truth: the biggest supply and pricing disruptions in pharma ra…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical research is supposed to be a race against time—enrolling patients, generating data, and moving therapies from hypothesis to approval. But there’s…